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The oncolytic peptide LTX-315 triggers immunogenic
cell death
H Zhou1,2,3,4,5,17, S Forveille1,2,3,4,17, A Sauvat1,2,3,4,5,17, T Yamazaki3,6,7,8,9,10, L Senovilla1,2,3,4,5, Y Ma1,2,3,4,5,11,12,
P Liu1,2,3,4,5, H Yang1,2,3,4,5,11,12, L Bezu1,2,3,4,5, K Müller1,2,3,4,5, L Zitvogel5,6,7,8,9,10, Ø Rekdal13,14,
O Kepp*,1,2,3,4,9,10 and G Kroemer*,1,2,3,4,15,16
LTX-315 is a cationic amphilytic peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/
BAK1-regulated, caspase-independent necrosis. Based on the observation that intratumorally injected LTX-315 stimulates a strong
T lymphocyte-mediated anticancer immune response, we investigated whether LTX-315 may elicit the hallmarks of immunogenic
cell death (ICD), namely (i) exposure of calreticulin on the plasma membrane surface, (ii) release of ATP into the extracellular space,
(iii) exodus of HMGB1 from the nucleus, and (iv) induction of a type-1 interferon response. Using a panel of biosensor cell lines and
robotized fluorescence microscopy coupled to automatic image analysis, we observed that LTX-315 induces all known ICD
characteristics. This conclusion was validated by several independent methods including immunofluorescence stainings (for
calreticulin), bioluminescence assays (for ATP), immunoassays (for HMGB1), and RT-PCRs (for type-1 interferon induction). When
injected into established cancers, LTX-315 caused a transiently hemorrhagic focal necrosis that was accompanied by massive
release of HMGB1 (from close-to-all cancer cells), as well as caspase-3 activation in a fraction of the cells. LTX-315 was at least as
efficient as the positive control, the anthracycline mitoxantrone (MTX), in inducing local inflammation with infiltration by myeloid
cells and T lymphocytes. Collectively, these results support the idea that LTX-315 can induce ICD, hence explaining its capacity to
mediate immune-dependent therapeutic effects.
Cell Death and Disease (2016) 7, e2134; doi:10.1038/cddis.2016.47; published online 10 March 2016
Although cytotoxic chemotherapeutics used for the treatment
of cancer often fail to achieve their ultimate goal – namely
curing the patient in a permanent manner, without later
relapse of the disease – there are a few examples in which
conventional chemotherapy achieves long-term effects.1,2
Beyond hematopoietic cancers, this applies for example to
anthracycline-based adjuvant chemotherapy of breast cancer,
which achieves a marked reduction in the relapse rate.3 The
extraordinary success of this treatment might be explained by
the fact that anthracyclines mobilize the immune system
against malignant cells. Thus, cancer cells treated with
anthracyclines in vitro elicits a T lymphocyte-mediated
immune response against tumor-associated antigens when
they are injected subcutaneously into immunocompetent
mice, thereby protecting mice against rechallenge with live
tumor cells of the same kind.4,5 In other words, anthracyclines
trigger immunogenic cell death (ICD).6–8
At the immunological level, it turned out that several pattern
recognition receptors are involved in the recognition of dying
cancer cells, meaning that their knockout or loss-of-function
mutation abolishes the anticancer immune response. This
applies for example to toll-like receptor 4 (TLR4) and formyl
peptide receptor 1 (FPR1), meaning that anthracyclines have
a reduced efficacy on tumors growing in Tlr4− /− or Fpr1− /−
mice (as compared with WT mice) and that breast
cancer patients bearing loss-of-function mutations in TLR4
or FPR1 have a comparatively poor prognosis after
adjuvant chemotherapy with anthracyclines.9,10 Neoadjuvant
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chemotherapy with anthracyclines causes a favorable change
in the ratio between cytotoxic T lymphocytes and immuno-
suppressive regulatory T cells, in particular in those patients
who manifest a complete pathological response.11 This
constitutes a further proof in favor of the concept that
anthracyclines mediate their antineoplastic effects via the
induction of an anticancer immune response.
Anthracycline-induced ICD relies on one of the biochemical
hallmarks of apoptosis, namely caspase activation. Thus, the
pharmacological pan-caspase inhibitor Z-VAD-fmk, as well as
transfection with the baculovirus inhibitor p35, do not interfere
with anthracycline-induced cell death (which apparently can
proceed in the absence of caspase activation), yet do abolish
the immunogenicity of anthracycline-induced cell death.4
Mechanistic studies revealed that caspase inhibition interferes
with several of the hallmarks of anthracycline-induced ICD,
namely the exposure of calreticulin (CALR) on the cell
surface,5,12 as well as with the release of ATP that is usually
associated with the blebbing phase of apoptosis.13,14 CALR
acts as a potent ‘eat-me’ signal when it is exposed on the
surface of stressed and dying cancer cells, facilitating the
transfer of tumor antigens to dendritic cells.15–17 The
mechanism of anthracycline-triggered CALR translocation to
the cell surface is complex and involves the obligatory
activation of caspase-8,18,19 as well as the co-translocation
of the disulfidisomerase PDIA3 (better known as ERp57).20
ATP acts as a potent chemoattractant, hence causing the
influx of myeloid cells into the tumor bed.21,22 ATP is released
through a partially autophagy-dependent mechanism that also
involves the caspase-3-mediated cleavage of pannexin-1
channels.13,21 Removal of CALR (by knockdown) or extra-
cellular ATP (by expression of the ATP-degrading ectoenzyme
ENTPDI, better known as CD39) abolishes the immunogeni-
city of anthracycline-triggered cell death, similarly as does
caspase inhibition.5,14 On the basis of these results, we have
been assuming that ICD was intimately linked to caspase
activation and that necrosis (which does not involve caspase
activation) would be intrinsically incompatible with ICD.
Indeed, induction of necrosis by freeze-thawing of otherwise
untreated cancer cells failed to yield an immunogenic
preparation; and freeze-thawing actually destroyed the immu-
nogenic properties of anthracycline-treated cells.4 Other
hallmarks of ICD, namely the exodus of HMGB1 from the
nuclei of dead cells and the induction of a type-1 interferon
response occur in a largely caspase-independent manner.9,23
In apparent contradiction with our findings, Patricia
Agostinis found that photodynamic therapy stimulates ICD
without capase-8 activation,24 establishing the existence of
another type of ICD (called ‘type-2 ICD’ as opposed to the
anthracycline-induced ‘type-1 ICD’) that differs in its signaling
mechanisms.6,25 In accord with this possibility, artificial
activation of necroptosis by chemical dimerization of a
modified transgenic RIPK3 (better known as RIP3) protein
can induce ICD.26 Hence, cell death that does not involve
caspase activation can be perceived as immunogenic. None-
theless, this cell death triggered by photodynamic therapy or
RIP3 activation does exhibit all major signs of ICD including
CALR exposure, ATP release, and HMGB1 exodus.24,26
There is yet additional, though indirect evidence that
necrosis may be immunogenic. Thus, LTX-315, a cationic
amphiphilic peptide derivative that permeabilizes inner
mitochondrial membranes and induces necrosis,27,28 is a
strong inducer of anticancer immune responses if injected into
tumors developing on immunocompetent mice.29,30 Indeed,
intratumoral injection of LTX-315 can lead to the eradication of
B16 melanomas, accompanied by an immune response that
protects cured mice against rechallenge with live B16
cells.29,30 Challenged by this observation, we investigated
whether LTX-315 can trigger ICD by characterizing the
hallmarks of ICD (CALR exposure, ATP release, HMGB1
exodus and type-1 interferon response). Our results indicate
that LTX-315 can induce all characteristics of ICD in a
caspase-independent manner in vitro. When injected in vivo,
into tumors, LTX-315 induces massive focal necrosis, followed
by immune infiltration.
Results and Discussion
LTX-315 induces calreticulin exposure. When added to
U2OS osteosarcoma cells, LTX-315 caused the induction of
CALR exposure, as detectable by immunofluorescence
staining of viable (propidium iodide-negative, PI−) cells. This
effect was detectable at LTX-315 doses that have no major
cytotoxic effect (12.5 and 25 μg/ml) as well around the half-
lethal dose (50 μg/ml) and was particular strong at 6 h of
treatment (Supplementary Figure 1). However, at a later time
point (24 h) no viable cells exposing CALR were detectable
(Figures 1a and b). Previous studies indicate that the
aggregation of CALR precedes its translocation to the plasma
membrane.31 U2OS cells stably transfected with a CALR-
green fluorescent protein (GFP) fusion protein manifested the
dose-dependent aggregation of CALR-GFP in cytoplasmic
granules after treatment with LTX-315 that was detectable at
6 h, as well as at 24 h (when the cells containing aggregated
CALR-GFP probably have lost their viability) (Figures 1c and d).
Interestingly, LTX-315 failed to induce the phosphorylation of
eukaryotic initiation factor 2α (eIF2α) in conditions in which
the positive control (induction of endoplasmic reticulum stress
with the SERCA pump inhibitor thapsigargin (THAP)) yielded
a major response (Supplementary Figure 2). These results
indicate that LTX-315 can stimulate CALR exposure through
a pathway that does not involve eIF2α phosphorylation,
hence resembling that induced by photodynamic therapy.24
LTX-315 induces the release of ATP and HMGB1. We next
investigated whether LTX-315 would be able to stimulate the
release of the two DAMPs ATP and HMGB1 from cancer
cells. For this, we first determined the capacity of LTX-315 to
reduce the staining of U2OS cells with quinacrine, a
fluorophore that selectively stains ATP-rich cytoplasmic
vesicles. LTX-315 caused the depletion of quinacrine-
positive vesicles (Figures 2a and b). Moreover, it provoked
an increase in extracellular ATP levels, as measured by
means of a bioluminescence reaction (Figure 2c). U2OS cells
stably expressing an HMGB1-GFP fusion protein in their
nuclei exhibited loss of the fluorescent signal upon short-term
culture (6 h) with LTX-315. At later time points, the few
adherent cells found in the cultures retained the HMGB1-
GFP-dependent fluorescent signal (Figures 3a and b). The
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release of HMGB1 into the culture supernatant by cells
treated with LTX-315 could be confirmed by means of a
sensitive ELISA (Figure 3c). In conclusion, LTX-315 can
stimulate the release of both DAMPs from cancer cells.
LTX-315 stimulates a type-1 interferon response. ICD
inducers can stimulate the production of type-1 interferon,
which act on type-1 interferon receptors (IFNAR) to stimulate
the transcription of a series of target genes including that of
Figure 1 Induction of CALR exposure by LTX-315. (a, b) U2OS cells were treated for the indicated period (6 or 24 h) with LTX-315, MTX, or CCCP. Cells were either subjected
to surface immunofluorescence staining to detect CALR in viable, PI-excluding cells (representative cytofluorometry pictograms in a and statistical analyses in b). Note that high
concentration of LTX-315 killed499% of the cells, meaning that the fraction of PI-negative cells was too low to appreciate CRTexposure among them. (c, d) U2OS cells stably
expressing a calreticulin-GFP fusion protein were treated with the indicated agents, fixed at the indicated time points, counterstained with the chromatin dye Hoechst 33342 and
subjected to automatic fluorescence microscopy (representative microphotographs in c and statistical analyses in d). Quantitative results are shown as means± S.D. of
triplicates. Asterisks indicate significant differences (unpaired Student's t-test) with respect to untreated controls. *Po0.05; **Po0.01; ***Po0.001
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MX1 (which codes for myxovirus (influenza) resistance 1,
MX1).32 The primary event leading to this type-1 interferon
response resides in the stimulation of toll-like receptor-3
(TLR3) by extracellular nucleic acids.33 To reveal this
phenomenon, we created a cell line expressing GFP under
the control of the MX1 promoter. Such cells are highly
reactive to the prototypical type-1 interferon, interferon-α1
(IFNα1), and hence become GFP positive. The conditioned
medium of LTX-315-treated cells also was able to stimulate
GFP expression by such biosensor cell lines, more so than
LTX-315-containing culture media (Figures 4a–d). In addition,
we found that LTX treatment of cells induced the expression
of mRNAs encoding several type-1 interferons including
IFNα2 and IFNβ1 (Figure 4e). We conclude from these results
that LTX-315 can stimulate a type-1 interferon response.
LTX-315 induces tumor necrosis and immune infiltration.
To further investigate the capacity of LTX-315 to stimulate an
anticancer immune response, we injected the product into
established MCA205 fibrosarcomas growing on C57Bl/6
mice. The injection of LTX-315 caused hemorrhagic necrosis
that, by macroscopic detection, was particularly detectable
1 day post injection (as opposed to 4 days post injection)
(Figure 5a). LTX-315 also caused persistent necrosis, which
was detectable as a de-coloration of the hematoxylin eosin
(HE) staining (Figures 5b–d). Within this necrotic area, we
found a major influx of immune/inflammatory cells with a
lymphocyte-like morphology that was particularly strong
1 day after LTX-315 injection (Figures 5e and f). Immuno-
fluorescence staining revealed that the necrotic areas had
lost all HMGB1 (Figure 6a; Supplementary Figure 3).
Figure 2 Release of ATP from cells exposed to LTX-315. U2OS cells were cultured in the indicated conditions with LTX-315, staurosporin (STS), or CCCP. Then, live cells
were stained with quinacrine and immediately analyzed by fluorescence microscopy. Representative images are shown in (a). Quantitative results (means±S.D. of triplicates)
are provided in (b). Furthermore, extracellular ATP was measured in the culture supernatant, as shown in (c). Asterisks indicate significant differences (unpaired Student's t-test)
with respect to untreated controls. *Po0.05; **Po0.01; ***Po0.001
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Surprisingly, a substantial fraction of the cells in the necrotic
area exhibited positivity for activated caspase-3 (CASP-3a),
in spite of the fact that their nuclei rarely had a shrunken
or fragmented morphology compatible with apoptosis
(Figure 6b). In contrast to anthracyclines, which induce a
major phosphorylation of eIF2α, LTX-315 failed to cause any
immunofluorescence-detectable sign of eIF2α phosphoryla-
tion (Figure 6c). However, LTX-315 and MTX were similar in
their capacity to provoke the influx of CD3+ T cells and F4/80+
macrophages into the tumor (Figures 7a and b). Hence,
LTX-315 triggers a local inflammatory and immune response
that is comparable in its magnitude to that induced by
anthracyclines.
Concluding remarks. In this study, we present ample
evidence that LTX-315 can induce all hallmarks of ICD
including CALR exposure, ATP release, HMGB1 exodus and
type-1 IFN responses when added to cultured cancer cells.
The lethal mode of action of LTX-315 has recently been
elucidated.27,28 LTX-315 preferentially enriches at mitochon-
drial membranes, causing their permeabilization, meaning
that the barrier function of both the inner and the outer
mitochondrial membrane is lost. Cells lacking the two pro-
apoptotic multidomain proteins from the BCL2 family, BAX
and BAK, were slightly less susceptible to LTX-315-mediated
killing than were control cells, although this protection was
only partial. Moreover, cells engineered to lose their
mitochondria (by transfection with Parkin followed by treat-
ment with a protonophore causing complete removal of the
organelles by mitophagy) became relatively resistant against
LTX-315, although this effect was rather partial as well.27,28 In
contrast, inhibition of caspases failed to subvert the cytotoxic
Figure 3 Release of nuclear HMGB1 from cells exposed to LTX-315. U2OS cells stably expressing an HMGB-GFP fusion protein were cultured in the indicated conditions
with LTX-315, staurosporin (STS), or CCCP. Cells then were fixed and subjected to automatic fluorescence microscopy. Representative images are provided in (a). Quantitative
results (means± S.D. of triplicates) are given in (b). Alternatively, parental U2OS cells were subjected to a similar treatment, followed by detection of HMGB1 in the culture
supernatant, as shown in (c). Asterisks indicate significant differences (unpaired Student's t-test) with respect to untreated controls. *Po0.05; **Po0.01; ***Po0.001
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Figure 4 Induction of a type-1 interferon response by LTX-315. (a–d) A schematic representation of the experimental design is shown in (a). LTX-315 was added at variable
concentrations to culture media (without cells, above) or U2OS cell cultures (below). Recombinant IFN-α1 was used as a positive control. After 24 h, the culture supernatants
were recovered and added to fresh cultures (1:16 dilution) of U2OS cells stably expressing GFP under the MX1 promoter (MX1-GFP). After an additional 48-h culture period, cells
were fixed, counterstained with Hoechst 33342, and subjected to automated fluorescence microscopy and image analysis. Representative images are shown in (b), raw data of
quantitations (means± S.D. of triplicates) in (b), and the subtraction of initially cell-free versus-cell-containing cultures in (d, e). Detection of type-1 interferons by RT-PCR. Cells
were incubated as indicated with variable amounts of LTX-315 for distinct periods and then subjected to mRNA extraction and RT-PCR. Asterisks indicate significant differences
(unpaired Student's t-test) with respect to untreated controls. *Po0.05; **Po0.01; ***Po0.001
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effects of LTX-315. Moreover, MCA205 cells used in the
in vivo experiments shown in this paper are fully susceptible
to killing by LTX-315, in spite of the fact that they lack
expression of the essential necroptotic signaling molecule
RIP3. Similarly, knockout of the necroptotic effector molecule
RIP3 did not affect the dose response of cell death induction
in TC1 lung cancer cells (Supplementary Figure 4). Alto-
gether, these data are compatible with the hypothesis that
LTX-315 essentially causes passive cell death, without any
major active contribution of lethal signal transduction path-
ways that are usually participating in the dismantling phases
of apoptosis or necroptosis.34,35
We previously demonstrated that killing cancer cells by
repeated freeze-thawing, which induces necrotic destruction,
fails to yield an immunogenic preparation,4 and this finding has
been confirmed in other experimental systems.26 In sharp
contrast, induction of necroptosis by chemical dimerization of
a modified RIP3molecule can induce ICD, a phenomenon that
involves the RIP1-dependent activation of an NF-κB-led
transcriptional program.26 Here, we show that LTX-315 also
can induce ICD in the context of a necrotic pathway that is
independent of RIP3 (and is not inhibited by necrostatin 1,
which inhibits RIP1),27,28 suggesting that different pathways
leading to necrosis can cause ICD. Obviously, the release of
ATP from cells cannot be dictated any more by caspases and
rather must occur in a passive manner (instead of the
caspase-dependent activation of Pannexin 1 channels).13,14
Nonetheless, we have not yet explored the question as to
whether the transcription of NF-κB-dependent genes would
contribute to the immunogenicity of LTX-315-induced cell
death. Several physical methods, including photodynamic
therapy, high hydrostatic pressure, and hyperthermia, have
been developed for the necrotic destruction of cancer cells
and actually can induce ICD.36,37 Altogether, these results
suggest that freeze-thawing may actually constitute an
exception among necrosis inducers with regard to its
incapacity to induce ICD. This might be related to the full
destruction of cells and subcellular structures by microcrystals
generated during this process (‘cryodamage’) with the
subsequent activation of hydrolases that may destroy DAMPs
or antigens required for immunogenicity.
In cell cultures, LTX-315 induces ‘pure’ necrosis, meaning
that it fails to stimulate the appearance of the morphological
and biochemical hallmarks of apoptosis (nuclear shrinkage or
fragmentation, activation of effector caspases).27,28 When
injected into tumors, it causes a focal hemorrhagic necrosis
that is rapidly filled by inflammatory cells including macro-
phages and T cells. Hence, local injection of LTX-315 into the
tumor is as efficient as MTX in stimulating a local inflamma-
tory/immune reaction. At difference with the in vitro results,
however, LTX-315-injected tumor sites accumulate cells that
stain with an antibody recognizing active, proteolytically
mature caspase-3. At present, the apparent discrepancy
between the incapacity of LTX-315 to induce caspase-3
activation in vitro and its in vivo effects is difficult to understand.
The frequency of cells staining for active caspase-3 is high,
suggesting that the phenomenon must occur in cancer (as
opposed to stromal and inflammatory) cells. Possibly, the
in vivo effects of LTX-315 are affected by altered pharmaco-
kinetics, as suggested by the fact that LTX-315-induced killing
Figure 5 Macroscopic and microscopic signs of necrosis induced by LTX-315
in vivo. MCA205 fibrosarcoma was established on C57/Bl6 mice and injected with
PBS (control, Ctr) or LTX-315. Tumors were harvested 1 or 4 days later and were
either photographed after excision to document their macroscopic appearance (a) or
subjected to HE staining (raw appearance in (b) and ratio of eosin over hematoxylin in
(c)) to quantify the area with low hematoxylin staining (d). Results in (d) are means
± S.E.M. for the indicated number of tumors. Representative HE staining patterns of
necrotic areas are shown in (e) and the number of infiltrating leukocytes per view field
were determined in (f). Asterisks indicate significant differences (unpaired Student's
t-test) with respect to PBS-treated controls. *Po0.05; **Po0.01; ***Po0.001
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is inhibited by high serum concentrations (Supplementary
Figure 5). However, high serum did not switch LTX-315-
induced necrosis to apoptosis, suggesting that other hitherto
unknown factors must contribute to LTX-315-induced
caspase-3 activation. As a possibility, DAMPs released from
a fraction of cells succumbing to LTX-315 through necrosis
might trigger apoptosis in adjacent cells.38 This possibility is
under active investigation in our laboratories.
Altogether, our present work demonstrates the possibility
that stimuli that a priori induce necrosis can stimulate local
immune reactions that ignite a strong anticancer immune
response. It will be interesting to explore the possibility of
rendering LTX-315-like molecules more specific, namely by
fusing them to targeting peptides, hence facilitating their
uptake bymalignant (rather than normal) cells. Moreover, it will
be important to compare peptides preferentially lysing distinct
organelles for their ICD-triggering capacity.
Materials and Methods
Cell culture and treatment. Unless otherwise indicated, chemicals were
obtained from Sigma-Aldrich (St. Louis, MO, USA). LTX-315 was obtained from Lytix
Biopharma (Oslo, Norway). Culture media were from Gibco-Invitrogen (Carlsbad,
CA, USA). U2OS cells were obtained from the American Type Culture Collection
(ATCC) and cultured under standard cell culture conditions (5% CO2; 37 °C) in a
water-saturated atmosphere within a cell culture incubator (HeraCell, Heraeus,
Germany). U2OS that were genetically engineered as described,31 were cultured in
DMEM GlutaMax supplemented with 10% FBS. In short, cells were stably
transduced or transfected with cDNA vectors coding for the indicated fluorescent
fusion proteins. Subsequently, stable expressing cells were selected by means of
Figure 6 Cell death and stress induced by LTX-315 in vivo. Subcutaneous MCA205 fibrosarcomas were injected locally with PBS (control, Ctr), LTX-315, or MTX. One or four
days later, tumor was retrieved and subjected to immunofluorescence staining to detect HMGB1 (a), activated caspase-3 (b), or phosphorylated eIF2α (c). Representative
staining patterns are shown on the left and quantitative results (each dot represents one view field) are shown on the right. Asterisks indicate significant differences (unpaired
Student's t-test) with respect to PBS-treated controls. *Po0.05; **Po0.01; ***Po0.001
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appropriate selection antibiotics and clones were obtained by single cell sorting
using a FACS DIVA (Becton Dickinson, Franklin Lakes, NJ, USA). Unless otherwise
indicated, staurosporin was used at 1 μM, carbonyl cyanide m-chlorophenyl
hydrazine (CCCP) at 100 μM, MTX at 1 μM, and THAP at 1 μM.
Interferon biosensor. For the detection of interferon-mediated responses,
U2OS cells were transfected with pEZX-PF02 (Genecopoeia, Rockville, MD, USA)
coding for eGFP under the control of the myxovirus (influenza virus) resistance 1
(MX1) promoter. Stably expressing cells were selected using puromycin and clones
were generated by single cell sorting using a FACS DIVA (Becton Dickinson).
Automated image acquisition. One day before the experiment, 4 × 103 cells
were seeded in tissue culture-treated 96-well μClear imaging plates (Greiner BioOne,
Frickenhausen, Germany) and incubated under standard tissue culture conditions. On
the following day, the cells were treated, and after incubation for 6 or 24 h the cells
were fixed with 3.7% formaldehyde solution containing 1 μM Hoechst 33342 overnight
at 4 °C. The fixative was changed to PBS, and the plates were subjected to automated
image analysis. For automated fluorescence microscopy, a robot-assisted Molecular
Devices IXM XL BioImager (Molecular Devices, Sunnyvale, CA, USA) equipped with
Sola light sources (Lumencor, Beaverton, OR, USA), adequate excitation and emission
filters (Semrock, Rochester, NY, USA), and a 16-bit monochromes sCMOS PCO.edge
5.5 camera (PCO, Kelheim, Germany) and a × 20 PlanAPO objective (Nikon, Tokyo,
Japan) was used to acquire six view fields/well, followed by image processing with the
custom module editor of the MetaXpress software (Molecular Devices). Depending on
the utilized biosensor cell line, the primary region of interest (ROI) was defined by a
polygon mask around the nucleus allowing for the enumeration of cells and (in the
case of HMGB1-GFP expressing cells) the quantification of nuclear HMGB1. Cellular
debris was excluded from the analysis, and secondary cytoplasmic ROIs were used for
the quantification of CALR-GFP or quinacrine containing vesicles. For the latter, the
images were segmented and analyzed for GFP granularity by comparing the standard
deviation of the mean fluorescence intensity of groups of adjacent pixels within the
cytoplasm of each cell to the mean fluorescence intensity in the same ROI using the
MetaXpress software (Molecular Devices).
Tissue immunohistochemistry and confocal imaging. Tumors upon
dissection were fixed with 3.7% of PFA for 4 h at ambient temperature. Then, the
tissue was incubated in 30% sucrose solution for 24 h at 4 °C. One half of the tumor
was used for hematoxylin eosin staining according to standard procedures, and the
other half was used for immunohistochemistry (IHC). The tissue was cut in 6-μm-
thick slices using a Cryostat CM (Leica, Mannheim, Germany) and was then
incubated with blocking buffer (10% FBS in PBS) for 30 min at RT and stained with
primary antibodies and secondary antibody-fluorochrome conjugates both diluted in
blocking buffer according to standard procedures. Coverslips were mounted in DAPI
containing Fluomount-G (Southernbiotech, Birmingham, AL, USA). Images were
acquired using a TCS SP 8 confocal microscope (Leica) equipped with a × 40 oil
objective (Nikon). The percentage of phenotypically altered cells was evaluated
using imageJ (http://imagej.nih.gov/ij/).
Determination of surface exposed CALR by immunofluores-
cence. Cells were collected and washed twice with cold PBS. Following the cells
were incubated with an anti-CALR antibody (ab2907; Abcam, Cambridge, UK)
diluted in cold blocking buffer (1% BSA in PBS) for 60 min on ice, followed by
washing and incubation with AlexaFluor 488-conjugates (Invitrogen) in blocking
buffer (for 30 min). Thereafter, cells were washed in cold PBS, PI was added to the
final concentration of 1 μg/ml, and samples were analyzed by means CyAn ADP
(Beckman Coulter) coupled to a Hypercite autosampler (IntelliCyte; Albuquerque,
NM, USA). The analysis was limited to living (PI−) cells. Data were statistically
evaluated using the R software (https://www.r-project.org).
Assessment of ATP secretion. For the detection of ATP containing
vesicles, the cells were labeled with quinacrine as described.12 In short, cells were
incubated with 5 μm quinacrine and 1 μg/ml Hoechst 33342 in Krebs-Ringer
solution (125 mM NaCl, 5 mM KCl, 1 mM MgSO4, 0.7 mM KH2PO4, 2 mM CaCl2,
6 mM glucose and 25 mM Hepes, pH 7.4) for 30 min at 37 °C. Thereafter, cells
were rinsed with Krebs-Ringer and living cells were microscopically examined.
Alternatively, the concentration of extracellular ATP was assessed by means of the
ENLITEN ATP assay (Promega, Madison, WI, USA), based on luciferin conversion,
Figure 7 Immune infiltrates induced by LTX-315 in vivo. Subcutaneous MCA205 fibrosarcomas were injected locally with PBS (control, Ctr), LTX-315, or MTX. One or four
days later, tumor was excised and subjected to immunofluorescence detection of CD3 (a) or F4/80 (b). Representative staining patterns are represented on the left and
quantitative results (each dot represents one view field) are shown on the right. Asterisks indicate significant differences (unpaired Student's t-test) with respect to PBS-treated
controls. *Po0.05; **Po0.01; ***Po0.001
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following the manufacturer’s instructions. Chemoluminescence was measured using
an i3 Paradigm multi-label reader (Molecular Devices).
Determination of extracellular HMGB1 concentration. Quantification
of HMGB1 in cell supernatants was performed by means of an enzyme-linked
immunosorbent assay (HMGB1 ELISA kit II, Shino Test Corporation, Tokyo, Japan)
following the manufacturer's instructions. Absorbance was analyzed by means of an i3
Paradigm multi-label reader (Molecular Devices).
Quantitative real-time PCR for interferon production. Total RNA
extraction and genomic DNA removal were performed with the GeneJet RNA
purification kit (ThermoScientific, Waltham, MA, USA) following the manufacturer's
instructions. Total RNA (5 μg from each sample) was reverse-transcribed into cDNA
with the Maxima first-strand cDNA synthesis kit (ThermoScientific) in the presence
of random primers and Deoxynucleoside Triphosphate (Invitrogen, Carlsbad, CA,
USA). Expression of IFN-related genes was analyzed by means of the Power SYBR
Green PCR Master Mix (ThermoScientific) mixed with primers (Invitrogen) on a
StepOnePlus Real-Time PCR System (ThermoScientific). qRT-PCR data were
invariably normalized to the expression levels of the housekeeping gene HPRT1.
Animals. Six- to seven-week-old female wild-type C57Bl/6 mice obtained from
Harlan France (Gannat, France) were maintained in the animal facility of the
Gustave Roussy Campus Cancer in specific pathogen-free conditions in a
temperature-controlled environment with 12 h light, 12 h dark cycles and received
food and water ad libitum. Animal experiments were in compliance with the EU
Directive 63/2010 and protocols. Protocols 2013_094A were approved by the Ethical
Committee of the Gustave Roussy Campus Cancer (CEEA IRCIV/IGR no. 26,
registered at the French Ministry of Research). MCA205 tumors were estabished in
C57Bl/6 host by injecting 500 000 cells subcutaneously. When tumor became
palpable, 300 μg of LTX-315 was injected intratumorily, and tumors were recovered
1 or 4 days post injection.
Statistical analyses. Unless otherwise specified, experiments were per-
formed in quadruplicates. Data were analyzed with the freely available software
R (https://www.r-project.org). Statistical significance was calculated using a two-
tailed Student's t-test with Welch correction, and P-valueso0.05 were considered
as statistically significant. Thresholds for each assay were applied based on the
Gaussian distribution of positive and negative controls.
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